Bayer: licensing agreement with Dewpoint Therapeutics

(CercleFinance.com) - Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics for a heart disease program to treat patients with dilated cardiomyopathy (DCM), which are characterized by carrying specific mutations.


This is the first option exercise in the research collaboration between Bayer and Dewpoint Therapeutics, which began in November 2019. It leverages Dewpoint's proprietary biomolecular condensate platform and Bayer's small molecule R&D capabilities to develop novel treatments for cardiovascular and renal diseases.

Dewpoint Therapeutics will receive an upfront payment and additional development and commercialization milestone payments of an estimated $424 million, excluding royalties.

' The emerging biomolecular condensate paradigm is expanding the traditional small molecule target space by unveiling new targets and new approaches to previously elusive targets. We are delighted to be part of this new wave of innovation with Dewpoint Therapeutics, as our ambition is to deliver transformative medicines to patients with unmet cardiovascular disease needs. said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer's pharmaceutical division.

Copyright (c) 2024 CercleFinance.com. All rights reserved.